Dr Reddy's CEO expects H2 FY2026-27 rebound, warns of fierce semaglutide generics market
Dr Reddy's CEO Erez Israeli expects the company to achieve a healthy performance in the second half of fiscal year 2026-27, contingent on resolving current issues with its semaglutide pipeline. Israeli also anticipates that the generics market for semaglutide will be ultra-competitive, with over 20 companies vying for market share.
Source:彭博市场 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Analysis of TB Coin’s Value: Multiple Projects Share the Same Code, but Investment Potential Varies
-
2
What Is VSC? An Overview of the Vyvo Coin (VSC) Project and Its Current Market Status
-
3
What is ANTS? It is a shared symbol used by multiple projects; be sure to verify which one you are investing in before proceeding.
-
4
When Will the Uniswap Decentralized Exchange Launch? An Analysis of Its Origins and Core Mechanisms
-
5
Analysis of OZONE Token Value: Distinguishing the Investment Potential of Ozonechain (OZO) and Ozone Metaverse ($OZONE)
-
6
WPC Coin Analysis: The Current Status and Future Prospects of World Peace Coin and WePiggy Coin
-
7
LTC Litecoin: A Review of Price Trends and Halving Events Over the Past Seven Years (2019–2026)
-
8
What Is KNC? An Analysis of the Functions and Trading Platform of KNC, the Core Token of Kyber Network
-
9
A Roundup of Key Listed Companies in the Metaverse: Who Are the Key Players in Building the Virtual World?
-
10
GHC (Galaxy Heroes Coin) Value Analysis: Project Overview and Investment Considerations
Markets Today
Recommended Reading












